ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0339

Evaluating Discordance between Bilateral Hip Bone Density Measurements in Individuals with Low Bone Mass

Anupama Shahane1, Nora Sandorfi2 and Alexis Ogdie1, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, USA, Philadelphia

Meeting: ACR Convergence 2025

Keywords: Dual energy x-ray absorptiometry (DEXA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Bone mineral density (BMD) measurement by dual X-ray absorptiometry (DXA) is the basis of World Health Organization (WHO) classification criteria for osteoporosis. Traditionally unilateral hip bone density has been measured and the utility of bilateral reporting remains unclear. Recent data have shown that a significant difference may be noted in bone density measurements between left and right hips with resultant failure to identify and treat individuals at high risk of fracture. In the 2023 Position Statement, the International Society of Clinical Densitometry (ISCD) noted that the impact of discordant hip bone density on diagnosis and monitoring of osteoporosis is a significant knowledge gap. This study aims to examine concordance vs discordance between left and right hip bone density measurement at a large hospital system. Results of this study may be helpful to further evaluate the impact and need for bilateral hip BMD testing as standard of care for osteoporosis screening.

Methods: A retrospective cohort study was performed using data from electronic medical record at the University of Pennsylvania. After IRB approval, patients with bilateral DXA were identified. A subset of charts with the following criteria were randomly selected for review: age 50 years or older, DXA report within the past 4 years within the health system, and diagnosis of osteopenia or osteoporosis. Manual chart review was conducted for capture of T scores for lumbar spine, left femoral neck, left total hip, right femoral neck and right total hip. We descriptively report baseline characteristics. Scatter plots were used to assess correlation between the right and left sides. Paired T tests were employed to test whether the left was significantly different from the right side for both the total hip and femoral neck.

Results: Within the health system, 29,258 patients > age 50 years had received a DXA scan at 3 primary sites between 2021 and 2024. The initial search was then narrowed to limit patients to those seen by Rheumatology providers (N&#3f1171). Among these, 85.7% patients were female and 81% were White. 200 charts were randomly selected among these and reviewed manually. 143 (71.5%) patients had DXA results reporting bilateral hip BMD. 27 (19%) patients had a T score difference of 0.5 between left and right femoral neck or total hip. 13 patients were classified into a different category: 2 patients with normal T score on one side vs low bone mass on the other side, and 11 patients with low bone mass on one side vs osteoporosis on the other side. This resulted in a reclassification rate of 7.8%, with 7% of patients with missed diagnosis of osteoporosis. Correlation between the two sides was high (Figure 1A and B) and there were no statistically significant differences between the left and right sides (Table 2).

Conclusion: In this retrospective study of patients >50 years, measurement of bilateral hip bone density demonstrated a high overall correlation between the two sides but resulted in a reclassification rate of 7% from low bone mass into osteoporosis when compared to measuring only one side. There may be a significant missed opportunity for primary fracture prevention which needs further examination.

Supporting image 1Table 1: Demographics

Supporting image 2Table 2: Difference between left and right femoral neck and total hip T scores

Supporting image 3Figure 1A and 1B: Scatter plots comparing right and left sides for femoral neck (A) and total hip (B)


Disclosures: A. Shahane: None; N. Sandorfi: Bristol-Myers Squibb(BMS), 2, Immunovant, 1, Johnson & Johnson, 1, 2, Novartis, 1; A. Ogdie: AbbVie, 2, 5, Amgen, 2, 5, 11, Bristol Myers Squibb, 2, 5, Celgene, 2, 5, CorEvitas, LLC, 2, 5, Eli Lilly, 2, 5, Forward Databank, 5, Gilead, 1, 2, Janssen, 2, 5, Kopa/Twill Health, 2, NIH/NIAMS, National Psoriasis Foundation, 5, Novartis, 2, 5, 11, Pfizer, 2, 5, 11, Rheumatology Research Foundation, 5, Spyre, 2, Takeda, 2, UCB, 2, 5, University of Pennsylvania, 5.

To cite this abstract in AMA style:

Shahane A, Sandorfi N, Ogdie A. Evaluating Discordance between Bilateral Hip Bone Density Measurements in Individuals with Low Bone Mass [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evaluating-discordance-between-bilateral-hip-bone-density-measurements-in-individuals-with-low-bone-mass/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-discordance-between-bilateral-hip-bone-density-measurements-in-individuals-with-low-bone-mass/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology